Skip to main content

ACM Biosciences receives support for Covid-19 vaccine

| News

ACM Biosciences receives support for Covid-19 vaccine

27.05.2021

Innosuisse, the Swiss Innovation Agency, is supporting the Basel-based biotechnology company ACM Biosciences with a grant. This is intended for the development of a stable Covid-19 mRNA vaccine.

ACM Biosciences and Steve Pascolo are together being supported by Innosuisse for the development of a stable Covid-19 mRNA vaccine according to a press release from the Basel-based biotechnology company. Pascolo is the Principal Investigator at the University Hospital Zurich (USZ) and Co-Founder of the German-Dutch company CureVac, which specializes in mRNA research. With Innosuisse’s grant ACM Biosciences and Pascolo plan to develop a novel vaccine with improved characteristics in terms of storage temperature, logistics and flexibility.

As such, the new vaccine would differ from the mRNA vaccines created thus far, which are unstable and require complex cooling solutions. ACM Biosciences plans to use artificial cell membranes for this that have been developed with a nanotechnology platform and are based on non-immunogenic polymersomes as a carrier. Peter Moran, CEO of ACM Biosciences, is quoted in the press release stating: “We are delighted to collaborate with Dr. Steve Pascolo with the support from Innosuisse to validate the polymersomes for mRNA delivery.”

His company was first established in September 2020 and has already had a successful funding round in April 2021. The company uses technology developed by ACM Biolabs in Singapore and licensed by ACM Biosciences. Pascolo explains: “A polymersome carrier would have a simpler structure than a lipid nanoparticle carrier, which is the current standard for mRNA vaccines. This could yield clear benefits such as higher stability with easier storage and handling, cheaper production and making global supply possible even in areas with poor infrastructure.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.